Gianluca Laus

1.3k total citations · 1 hit paper
27 papers, 911 citations indexed

About

Gianluca Laus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gianluca Laus has authored 27 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Gianluca Laus's work include Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (12 papers) and Lung Cancer Research Studies (5 papers). Gianluca Laus is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (12 papers) and Lung Cancer Research Studies (5 papers). Gianluca Laus collaborates with scholars based in United States, United Kingdom and Spain. Gianluca Laus's co-authors include James Chih‐Hsin Yang, Suresh S. Ramalingam, Tony Mok, Myung‐Ju Ahn, Yi‐Long Wu, Thomas John, Frances A. Shepherd, Vassiliki A. Papadimitrakopoulou, J. Carl Barrett and Barbara Collins and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Gianluca Laus

26 papers receiving 897 citations

Hit Papers

Analysis of acquired resistance mechanisms to osimertinib... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    2023 95 citations Juliann Chmielecki, Tony Mok et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gianluca Laus United States 12 694 637 320 200 62 27 911
Jih‐Hsiang Lee Taiwan 19 561 0.8× 669 1.1× 347 1.1× 196 1.0× 59 1.0× 37 1.0k
Shinnosuke Ikemura Japan 18 487 0.7× 485 0.8× 494 1.5× 233 1.2× 66 1.1× 46 959
Reiko Kaji Japan 20 1.0k 1.4× 793 1.2× 236 0.7× 249 1.2× 59 1.0× 44 1.2k
Francesca Casaluce Italy 15 462 0.7× 512 0.8× 326 1.0× 140 0.7× 56 0.9× 38 841
Osvaldo Rudy Aren Chile 12 647 0.9× 489 0.8× 310 1.0× 189 0.9× 78 1.3× 22 841
Toshiki Takemoto Japan 15 616 0.9× 527 0.8× 381 1.2× 161 0.8× 83 1.3× 40 957
Marcello Tiseo Italy 3 659 0.9× 511 0.8× 425 1.3× 214 1.1× 73 1.2× 9 918
Assunta Sgambato Italy 15 416 0.6× 441 0.7× 293 0.9× 125 0.6× 53 0.9× 31 742
Lilia Stelmakh Russia 4 1.1k 1.5× 935 1.5× 226 0.7× 159 0.8× 58 0.9× 8 1.2k
Sumie Koike Japan 13 506 0.7× 669 1.1× 520 1.6× 199 1.0× 83 1.3× 19 1.0k

Countries citing papers authored by Gianluca Laus

Since Specialization
Citations

This map shows the geographic impact of Gianluca Laus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gianluca Laus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gianluca Laus more than expected).

Fields of papers citing papers by Gianluca Laus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gianluca Laus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gianluca Laus. The network helps show where Gianluca Laus may publish in the future.

Co-authorship network of co-authors of Gianluca Laus

This figure shows the co-authorship network connecting the top 25 collaborators of Gianluca Laus. A scholar is included among the top collaborators of Gianluca Laus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gianluca Laus. Gianluca Laus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brandão, Mariana, Jon Zugazagoitia, Anne‐Marie C. Dingemans, et al.. (2024). Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).. Journal of Clinical Oncology. 42(16_suppl). 8583–8583. 3 indexed citations
2.
Kyi, Chrisann, Sylvie Rottey, Ignacio Melero, et al.. (2024). Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2520–2520. 4 indexed citations
3.
Ekman, Simon, Zsolt Cselényi, Andrea Varrone, et al.. (2023). Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study. Clinical and Translational Science. 16(6). 955–965. 7 indexed citations
4.
Chmielecki, Juliann, Tony Mok, Yi‐Long Wu, et al.. (2023). Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications. 14(1). 1071–1071. 95 indexed citations breakdown →
5.
Papadimitrakopoulou, Vassiliki A., Tony Mok, Ji‐Youn Han, et al.. (2020). Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology. 31(11). 1536–1544. 183 indexed citations
6.
Ekman, Simon, Andrea Varrone, Aurelija Jučaitė, et al.. (2019). P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases. Journal of Thoracic Oncology. 14(10). S842–S842. 1 indexed citations
7.
Yang, James Chih‐Hsin, Frances A. Shepherd, Dong‐Wan Kim, et al.. (2019). Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology. 14(5). 933–939. 164 indexed citations
8.
Tsuboi, Masahiro, Roy S. Herbst, Thomas John, et al.. (2019). Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection. Annals of Oncology. 30. v589–v589. 4 indexed citations
9.
10.
Papadimitrakopoulou, Vassiliki A., Yi‐Long Wu, J. Y. Han, et al.. (2018). Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Annals of Oncology. 29. viii741–viii741. 178 indexed citations
11.
Meador, Catherine B., Yuebi Hu, James Chih‐Hsin Yang, et al.. (2018). Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. Journal of Clinical Oncology. 36(15_suppl). 9071–9071. 2 indexed citations
12.
Mitsudomi, Tetsuya, M-J. Ahn, Lyudmila Bazhenova, et al.. (2017). Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies. Annals of Oncology. 28. v482–v482. 14 indexed citations
13.
Petty, Russell, Alan Anthoney, Jean‐Philippe Metges, et al.. (2016). Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). Cancer Chemotherapy and Pharmacology. 77(4). 819–827. 16 indexed citations
14.
Salazar, Ramón, Jean Philippe Metges, David Alan Anthoney, et al.. (2013). IMAGE, a randomized phase Ib/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer.. Journal of Clinical Oncology. 31(4_suppl). 92–92. 2 indexed citations
15.
Morgillo, Floriana, Erika Martinelli, Teresa Troiani, et al.. (2008). Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells. Molecular Cancer Therapeutics. 7(6). 1698–1707. 21 indexed citations
16.
Avallone, Antonio, Elena Di Gennaro, Francesca Bruzzese, et al.. (2007). Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Anti-Cancer Drugs. 18(7). 781–791. 14 indexed citations
17.
Pepe, Stefano, et al.. (2006). Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54p53wt and U251p53mut glioblastoma cell lines. Pharmacological Research. 55(1). 49–56. 18 indexed citations
18.
Cascone, Tina, Floriana Morgillo, Gianluca Laus, Sara Pepe, & Fortunato Ciardiello. (2006). 397 POSTER Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines. European Journal of Cancer Supplements. 4(12). 122–122. 2 indexed citations
19.
20.
Morelli, Maria Pia, Tina Cascone, Teresa Troiani, et al.. (2005). Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology. 16. iv61–iv68. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jih‐Hsiang Lee Breakdown of academic impact, for papers by Shinnosuke Ikemura Breakdown of academic impact, for papers by Reiko Kaji Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Osvaldo Rudy Aren Breakdown of academic impact, for papers by Toshiki Takemoto Breakdown of academic impact, for papers by Marcello Tiseo Breakdown of academic impact, for papers by Assunta Sgambato Breakdown of academic impact, for papers by Lilia Stelmakh Breakdown of academic impact, for papers by Sumie Koike
Rankless by CCL
2026